Health Canada Has Granted a New Health Claim Specific to Immunocal

Vaudreuil-Dorion, May 12, 2015 (Newswire.com) - Immunocal® First to be Granted Strength and Performance Claim for a Stand-Alone Whey Protein by Health Canada

Immunotec Inc. (TSXV: IMM) a direct-to-consumer company and leader in the nutritional industry (the “Company” or “Immunotec”) announced today that Health Canada has granted a new health claim specific to Immunocal’s ability to help increase muscle strength and enhance performance when combined with regular exercise.

“To be the first in Canada to obtain a performance claim for a stand-alone whey protein isolate reinforces our leadership position in the health and wellness industry and when combined with our existing immunity claim, gives the Immunocal brand unique positioning. These milestones are the fruition of over four decades of research at leading university hospitals in Canada and abroad.” said Mr. John Molson, Vice-President of Research and Development. Mr. Molson also stated, “While at first glance this claim may seem athlete specific, the application is much broader given the importance of maintaining muscle strength during the aging process.”

The published findings of two peer-reviewed, double blind, randomized, placebo controlled clinical trials were used to support the application. The most recent study, run at Institut de recherches cliniques de Montréal (IRCM) and published in the JOURNAL OF NUTRITION HEALTH AND AGING (2015), found that Immunocal imparted a performance benefit of approximately 10% in a model of resistance exercise in an elderly population of between 65 years to 88 years. The first study exploring Immunocal’s effect on muscular performance was conducted at the Montreal Children’s hospital and published in the Journal of Applied Physiology (1999). It demonstrated that consumption was associated with an average increase of 13.5% in peak power and thirty second work capacity in a younger population of 20 year olds.

About Immunocal

Immunocal is a specially formulated cysteine-rich whey protein isolate, developed and marketed worldwide by Immunotec over the past 20 years. It initially secured a Health Canada NPN (Natural Product Number) on November 11, 2007 for the health claim “Immunocal is a natural source of the glutathione precursor cysteine for the maintenance of a strong immune system.”

About Immunotec Inc.

Immunotec Inc. is a Canadian-based company ranked in the DSN Global 100 list. The Company develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S. and Mexico. The Company offers an extensive family of nutritional products targeting health, wellness, weight management, as well as energy and fitness. The Immunocal family of products is supported by over 40 published articles and supporting science in the medical and scientific literature. 

The Company files its continuous disclosure documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

John Molson, Vice-President of Research and Development

Immunotec Inc.  (450) 510-4450.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec’s most recent Management's Discussion and Analysis and Annual Information Form which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.